TNG:EPA
Transgene SA
€0,68
0,00%
(0,00) 1D
20 ຕ.ລ., 9 ໂມງ 25 ນາທີ 32 ວິນາທີ GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for TNG...
Open
€0,68
High
€0,68
Low
€0,68
Mkt. cap
189,70 ລ້ານ
Avg. vol.
111,65 ພັນ
Volume
640,00
52-wk high
€1,50
52-wk low
€0,68
EPS
€-0,17
Shares outstanding
278,56 ລ້ານ
No. of employees
152
Open
€0,68
High
€0,68
Low
€0,68
Mkt. cap
189,70 ລ້ານ
Avg. vol.
111,65 ພັນ
Volume
640,00
52-wk high
€1,50
52-wk low
€0,68
EPS
€-0,17
Shares outstanding
278,56 ລ້ານ
No. of employees
152
News stories
From web sources and news partners
Simply Wall Street
·
4 ນາທີກ່ອນ
Why Is TTM Technologies (TTMI) Buying Ophir Optics For $650 Million?
TradingView
·
1 ຊົ່ວໂມງກ່ອນ
Asia’s Bitcoin Play Hits Wall Street: Metaplanet Set to Buy This Nasdaq-Listed Company for BTC Treasury Operations
The Motley Fool
·
20 ນາທີກ່ອນ
IVV vs. SPY: Which S&P 500 ETF Is the Better Buy for Long-Term Investors?
Yahoo Finance
·
53 ນາທີກ່ອນ
Should You Wait Until After the Midterm Elections to Buy the S&P 500?
Profile
Transgene S.A. is a French biotechnology company founded in 1979. It is based in Illkirch-Graffenstaden, near Strasbourg, Alsace. The company develops and manufactures immunotherapies for the treatment of cancer. Based on viral vectors, these therapies stimulate the immune defenses of patients to specifically target cancer cells.
Transgene has two technological platforms based on these respective approaches: individual therapeutic vaccines, shared antigens cancer vaccines oncolytic viruses.
Transgene's portfolio consists of four products currently in clinical development. Its lead product TG4050, a neoantigen individualized therapeutic cancer vaccine is currently being developed in a randomized Phase I/II trial in the adjuvant treatment of head and neck cancer.
The company is listed on the regulated market of Euronext in Paris. Wikipedia
About Transgene SA